Telehealth Giant Halts Sale of Compounded Wegovy Pill After Regulatory and Legal Threats
In a dramatic reversal, telehealth company Hims & Hers has abandoned its plan to offer a knockoff version of the groundbreaking weight-loss pill Wegovy, just two days after announcing the controversial product. The decision came on Saturday, following intense pressure from both the Food and Drug Administration and pharmaceutical giant Novo Nordisk, which manufactures the original medication.
Rapid Announcement and Swift Retreat
The company had initially revealed on Thursday that it would sell a compounded version of the new Wegovy pill, which Novo Nordisk only began marketing last month. This announcement triggered an immediate legal threat from Novo Nordisk, followed by a decisive statement from the FDA on Friday. The regulatory body declared its intention to restrict access to the active ingredients required to copy popular GLP-1 weight-loss medications like Wegovy, Ozempic, and Zepbound.
Despite the public withdrawal announcement made on social media platform X earlier on Saturday, Hims & Hers' own website continued to promote the new semaglutide pill offering well into the afternoon. Semaglutide is the chemical name for Wegovy, highlighting the direct nature of the intended copy.
Company Statement and Industry Conversations
"Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment," Hims & Hers stated. The company emphasized its ongoing commitment to providing "safe, affordable, and personalized care" to millions of Americans who rely on its services.
Notably, the statement did not clarify whether the FDA's actions would affect the compounded injectable weight-loss medications that Hims & Hers currently sells. This leaves open questions about the future of its broader GLP-1 drug portfolio.
Pricing Strategy and Market Context
The San Francisco-based telehealth firm had planned to aggressively undercut Novo Nordisk's pricing. While the official Wegovy pill costs $149 per month, Hims & Hers intended to offer its version at just $49 for the first month and $99 per month thereafter. This pricing strategy is consistent with the company's historical approach; it initially gained traction by offering affordable generic versions of drugs for conditions like hair loss and erectile dysfunction before expanding into the lucrative obesity medication market.
Regulatory Landscape and Compounding Loopholes
The compounded medicine that Hims & Hers planned to sell was not FDA-approved and had not undergone clinical trials to demonstrate efficacy. The FDA typically permits specialty pharmacies and other entities to produce compounded versions of brand-name drugs only during shortages. The explosive demand for GLP-1 drugs in recent years had created a multibillion-dollar market opportunity, with many patients willing to pay out-of-pocket.
In 2024, the FDA declared that GLP-1 drugs were no longer in shortage, which should have ended the compounding practice. However, companies like Hims & Hers exploited an exception that allows compounding when a prescription is customized for an individual patient, enabling them to continue selling their versions.
Industry Reactions and Future Developments
Novo Nordisk, which plans to feature its FDA-approved Wegovy pill in a celebrity-studded Super Bowl advertisement on Sunday, did not immediately comment on Hims & Hers' decision to withdraw the knockoff. Meanwhile, rival drugmaker Eli Lilly anticipates FDA approval for an oral version of its orforglipron weight-loss medication later this spring. Despite this competition, Wegovy remains the first weight-loss pill to reach the market, securing its pioneering status.
This episode underscores the intense regulatory and competitive pressures in the rapidly expanding weight-loss medication sector, where telehealth companies and pharmaceutical giants are increasingly clashing over market share and regulatory boundaries.
